Arcutis director Welgus proposes $127K share sale

Howard Welgus also reported two earlier ARQT common-stock sales of 4,730 shares each, dated August 17 and September 15, 2026.

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) director Howard Welgus reported a proposed sale of 4,728 common shares, with an aggregate market value of $127,325.04. Merrill Lynch is listed as the broker, NASDAQ as the exchange, and October 15, 2026, as the approximate sale date.

Welgus also reported earlier sales of 4,730 shares on August 17, 2026, for $123,834.71, and 4,730 shares on September 15, 2026, for $114,371.40.

Key Figures

Proposed sale: 4,728 shares Aggregate market value: $127,325.04 Earlier sale: 4,730 shares +3 more

6 metrics

Proposed sale 4,728 shares Common stock; approximate sale date October 15, 2026.

Aggregate market value $127,325.04 Proposed sale.

Earlier sale 4,730 shares August 17, 2026; $123,834.71.

Earlier sale $123,834.71 4,730 shares sold August 17, 2026.

Earlier sale 4,730 shares September 15, 2026; $114,371.40.

Earlier sale $114,371.40 4,730 shares sold September 15, 2026.

Key Terms

Rule 144, Restricted Stock Vesting, Stock Option Exercise

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Stock Option Exercise financial

"Stock Option Exercise"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARQT shares does Howard Welgus propose to sell?

Howard Welgus reported a proposed sale of 4,728 common shares, with an aggregate market value of $127,325.04. The approximate sale date is October 15, 2026.

What ARQT shares did Howard Welgus sell in the prior three months?

Welgus reported sales of 4,730 shares on August 17, 2026, for $123,834.71 and 4,730 shares on September 15, 2026, for $114,371.40.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 03:57 PM EDT Accepted by SEC EDGAR 10/15/2026 - 03:56 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns Gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Howard Welgus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	4728	127325.04	125691961	10/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			634	06/04/2026	NA
Common	11/20/2019	Stock Option Exercise	Arcutis Biotherapeutics			822	10/15/2026	Cash
Common	05/31/2023	Stock Option Exercise	Arcutis Biotherapeutics			1018	10/15/2026	Cash
Common	06/14/2024	Stock Option Exercise	Arcutis Biotherapeutics			2254	10/15/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	08/17/2026	4730	123834.71
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	09/15/2026	4730	114371.4

144: Remarks and Signature

Remarks
Date of Notice	10/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Howard Welgus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)